GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of Procedural Order in Federal GranuFlo Recall Litigation

Share Article

The Firm is evaluating GranuFlo recall lawsuits on behalf of dialysis patients who allegedly experienced cardiac arrest, heart attacks, stroke, sudden cardiac death, or other side effects within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte dialysis concentrates.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We have heard from numerous dialysis patients who allegedly experienced frightening and life-threatening heart problems following treatment with either GranuFlo or NaturaLyte.

GranuFlo lawsuits filed in the wake of the recent recall of GranuFlo and NaturaLyte dialysis concentrates have begun to move forward in a multidistrict litigation established in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the judge overseeing the GranuFlo recall litigation issued an Order on April 5th governing the practices and procedures in all actions transferred to the multidistrict litigation. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“We have heard from numerous dialysis patients who allegedly experienced frightening and life-threatening heart problems following treatment with either GranuFlo or NaturaLyte. We are pleased to see that the GranuFlo recall litigation has begun to move forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the GranuFlo recall.

GranuFlo and NaturaLyte Recall
GranuFlo and NaturaLyte are marketed by Fresenius Medical Care, and used during dialysis to reduce the amount of acid in the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products, which would later be deemed a Class I GranuFlo recall by the U.S. Food & Drug Administration (FDA). Class I recalls are the agency’s most serious type, and are issued when a medical product poses a significant risk of serious injury or death.*

According to a New York Times report published last summer, both GranuFlo and NaturaLyte were used in dialysis clinics owned by Fresenius Medical Care, as well an estimatd 125,000 customer clinics outside the Fresenius network. Months before the announcement of the GranuFlo recall, Fresenius had issued a memo to dialysis clinics within its own network warning doctors practicing at those facilities that GranuFlo had been associated with serious heart side effects, and advised the physicians to adjust dosage in order to avoid excessive levels of bicarbonate in the blood. The FDA has since launched an investigation to determine if Fresenius Medical Care’s failure to issue an earlier warning to its customer clinics regarding the significant dangers associated with GranuFlo and NaturaLyte may have violated the law.**

The federal GranuFlo recall litigation was established last month by the U.S. Judicial Panel on Multidistrict litigation. According to the Panel’s March 29th Transfer Order, the consolidated litigation consisted of 11 federal claims filed since the GranuFlo recall. However, dozens of potential tag-along actions were also pending in a number of additional federal districts, the Panel said. Court filings show that plaintiffs in GranuFlo lawsuits allege Fresenius Medical Care was aware of the heart risks associated with GranuFlo and NaturaLyte, but failed to provide adequate warnings regarding those risks.

Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling (877) 779-1414.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

*fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflodialysislawsuits.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website